Transition from Intravenous Epoprostenol to Intravenous Treprostinil in Pulmonary Hypertension
Transition from Intravenous Epoprostenol to Intravenous Treprostinil in Pulmonary Hypertension
About this item
Full title
Author / Creator
Publisher
New York, NY: Am Thoracic Soc
Journal title
Language
English
Formats
Publication information
Publisher
New York, NY: Am Thoracic Soc
Subjects
More information
Scope and Contents
Contents
Intravenous epoprostenol improves exercise capacity and survival in patients with pulmonary arterial hypertension. The prostacyclin analog treprostinil is also efficacious by subcutaneous infusion, is easier to administer, and has a longer half-life. With the demonstration of bioequivalence between subcutaneous and intravenous treprostinil, intrave...
Alternative Titles
Full title
Transition from Intravenous Epoprostenol to Intravenous Treprostinil in Pulmonary Hypertension
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_68884381
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_68884381
Other Identifiers
ISSN
1073-449X
E-ISSN
1535-4970
DOI
10.1164/rccm.200505-766OC
